2026-08-27T12:18:43-05:00 2025-12-31 946214841 ARMANINO ADVISORY LLC 1520 S FIFTH STREET SUITE 309 ST CHARLES MO 63303 990 2025-01-01 272233336 PEDAL THE CAUSE PEDA 3147871990 9288 DIELMAN INDUSTRIAL DRIVE ST LOUIS MO 63132 DAVID DRIER EXECUTIVE DIRECTOR 3147871990 2026-08-21 1 JENNIFER M VACHA P01251998 6362553000 2026-08-18 2025 2025-03-06 01:10:19Z DAVID DRIER 9288 DIELMAN INDUSTRIAL DRIVE ST LOUIS MO 63132 7465739 0 X WWW.PEDALTHECAUSE.ORG X 2010 MO TO CONDUCT AN ANNUAL FUNDRAISING BIKE CHALLENGE TO RAISE AWARENESS AND FUNDS FOR CANCER RESEARCH. 30 30 12 710 0 0 9051296 6990092 378584 318912 96012 109535 -62442 -79647 9463450 7338892 5204913 5042167 0 0 1139109 1262612 0 0 765106 1372893 1448164 7716915 7752943 1746535 -414051 3191041 2750782 206559 180351 2984482 2570431 X OUR MISSION IS TO PROVIDE FUNDING FOR CANCER RESEARCH AT SITEMAN CANCER CENTER AND SITEMAN KIDS AT ST. LOUIS CHILDREN'S HOSPITAL THROUGH OUR ANNUAL CYCLE CHALLENGE. IT IS OUR HOPE THAT RESEARCH FUNDED BY PEDAL THE CAUSE WILL ULTIMATELY LEAD TO A CURE FOR CANCER. 0 0 6583079 5042167 333913 IN 2025, OVER 3,800 ADULTS AND CHILDREN PARTICIPATED IN PEDAL THE CAUSE, SUPPORTED BY 700 VOLUNTEERS, WHO TOGETHER RAISED OVER $5.0 MILLION TO FUND CANCER RESEARCH. OVER THE PAST 16 YEARS, PEDAL THE CAUSE HAS CUMULATIVELY DONATED $56 MILLION SUPPORTING 255 ADULT AND PEDIATRIC CANCER RESEARCH PROJECTS. FOR EVERY $1 PEDAL THE CAUSE DONATES TO CANCER RESEARCH, RESEARCHERS HAVE SUCCESSFULLY ATTRACTED SIGNIFICANT ADDITIONAL EXTERNAL FUNDING TO FURTHER THEIR RESEARCH, AVERAGING $14 FOR EVERY $1 INITIAL AWARD. IN 2025, PEDAL THE CAUSE EFFECTIVELY DISTRIBUTED 85% OF ITS REVENUE TO PROGRAM SERVICES. (CONTINUED ON SCHEDULE O)MAJOR BREAKTHROUGHS MADE POSSIBLE BY PEDAL THE CAUSE FUNDS INCLUDE THE DEVELOPMENT OF DNA AND PEPTIDE VACCINES FOR MULTIPLE CANCER TYPES, CANCER GOOGLES TO HELP SURGEONS SEE CANCER CELLS, IMMUNOTHERAPY HARNESSING OUR BODY'S 'NATURAL KILLER' CELLS AND CUTTING-EDGE RESEARCH IN THE UNDERSTANDING OF CANCER STEM-CELLS. PEDAL THE CAUSE FUNDS HAVE BEEN INSTRUMENTAL IN OBTAINING SPORE (SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE) GRANTS IN LEUKEMIA AND PANCREATIC CANCER, WHICH LEAD A NATIONAL GROUP OF EXPERTS IN COLLABORATIVE RESEARCH. PEDAL THE CAUSE FUNDED CLINICAL TRIALS ARE A KEY COMPONENT OF THE ROBUST CLINICAL TRIAL PROGRAM AT SITEMAN CANCER CENTER, WHICH RANKS AS THE LARGEST CANCER CLINICAL TRIALS PROGRAM IN THE MIDWEST AND THIRD LARGEST IN THE COUNTRY. SIGNIFICANT 2025 EXTERNAL FUNDING INCLUDED:LUNG CANCER & SMOKING CESSATIONLI-SHIUN CHEN, MD, MPH, SCD AND AIMEE JAMES, PHD, MPH RECEIVED A SIP RDA AWARD IN 2020 FOR THEIR PROJECT, "IMPLEMENTING MULTILEVEL SMOKING CESSATION INTERVENTIONS TO REDUCE RURAL CANCER DISPARITY." THEIR RESEARCH AIMED TO REDUCE THE HIGH SMOKING RATES AND ASSOCIATED CANCER DISPARITIES IN RURAL SOUTHERN ILLINOIS BY DEVELOPING A MULTI-LEVEL APPROACH TO HELP PATIENTS QUIT SMOKING. WITH PEDAL THE CAUSE SUPPORT, THE TEAM CREATED A COST-EFFECTIVE SMOKING CESSATION MODEL THAT CONNECTED TWO TO THREE TIMES MORE PATIENTS WITH TREATMENT AND ACHIEVED THREE TIMES GREATER QUIT SUCCESS THAN PREVIOUS APPROACHES, IMPROVING CANCER PREVENTION EFFORTS ACROSS RURAL COMMUNITIES. BUILDING ON THESE RESULTS, THE TEAM LEVERAGED THEIR WORK INTO A PRESTIGIOUS SIX-YEAR UG3/UH3 AWARD FROM THE NATIONAL CANCER INSTITUTE (NCI) TO EXPAND PRECISION TOBACCO TREATMENT FOR CANCER SURVIVORS. $6.7 MILLION IN NATIONAL CANCER INSTITUTE FUNDING RECEIVED IN 2025. HEMATOLOGIC/BLOOD CANCERYOON-A KANG, PHD RECEIVED A SIP RDA AWARD IN 2025 FOR HER PROJECT, "TARGETING MYELOID-BIASED MULTIPOTENT PROGENITOR TO REBALANCE LINEAGE OUTPUT IN MPNS." THE PROJECT FOCUSES ON DEVELOPING A NEW TREATMENT STRATEGY FOR MYELOPROLIFERATIVE NEOPLASMS (MPNS) BY TARGETING MULTIPOTENT PROGENITOR 3 (MPP3) CELLS, WHICH PLAY A KEY ROLE IN THE OVERPRODUCTION OF BLOOD CELLS SEEN IN THESE CANCERS. DR. KANG'S RESEARCH IS INVESTIGATING HOW REGULATING MPP3 BLOOD CELL PRODUCTION MECHANISMS COULD FORM THE FOUNDATION OF A BROADLY EFFECTIVE THERAPY FOR MPN PATIENTS REGARDLESS OF THEIR SPECIFIC GENETIC MUTATION. $860,000 IN AMERICAN CANCER SOCIETY FUNDING TO BE RECEIVED IN 2026. BREAST & OVARIAN CANCER PREVENTIONJOHN KRAIS, PHD RECEIVED A SIP RDA AWARD IN 2024 FOR HIS PROJECT, "TMEJ AND BRCA1 MUTANT TUMOR DEVELOPMENT." HIS RESEARCH INVESTIGATES HOW DNA DAMAGE ACCUMULATES AND IS REPAIRED IN CELLS CARRYING BRCA1 MUTATIONS, WITH THE GOAL OF PREVENTING THESE HIGH-RISK CELLS FROM BECOMING CANCEROUS. BY STUDYING A DNA REPAIR PATHWAY KNOWN AS POLYMERASE THETA-MEDIATED END JOINING (TMEJ), DR. KRAIS IS LAYING THE GROUNDWORK FOR A POTENTIAL NEW CANCER PREVENTION STRATEGY FOR INDIVIDUALS WITH INHERITED BRCA1 AND BRCA2 MUTATIONS. THE PROMISING PRELIMINARY DATA GENERATED THROUGH PEDAL THE CAUSE FUNDING LED TO MULTIPLE COMPETITIVE RESEARCH AWARDS THAT WILL ACCELERATE THIS WORK TOWARD FUTURE CLINICAL APPLICATIONS. $2.45 MILLION IN EXTERNAL FUNDING RECEIVED IN 2025, INCLUDING AN R35 AWARD FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES, AN OVARIAN CANCER RESEARCH FUND AWARD, AND A CANCER RESEARCH FOUNDATION GRANT. CHEMOTHERAPY SIDE EFFECTS & HEART HEALTHNIMA MOSAMMAPARAST, MD, PHD AND KORY LAVINE, MD, PHD RECEIVED A SIP RDA AWARD IN 2019 FOR THEIR PROJECT, "ALKYLATING CHEMOTHERAPIES PROMOTE HEART FAILURE BY TARGETING TISSUE RESIDENT CARDIAC MACROPHAGES." THEIR RESEARCH EXAMINED WHY COMMONLY USED CHEMOTHERAPY DRUGS CAN CAUSE LONG-TERM HEART DAMAGE IN CANCER SURVIVORS. THE TEAM DISCOVERED THAT DIFFERING RESPONSES IN HEALTHY TISSUES ARE A MAJOR CONTRIBUTOR TO THESE LASTING SIDE EFFECTS, CREATING NEW OPPORTUNITIES TO REDUCE TREATMENT-RELATED HEART FAILURE WHILE PRESERVING THE EFFECTIVENESS OF CANCER THERAPIES. THESE DISCOVERIES ALSO OPENED NEW AVENUES OF INVESTIGATION INTO HOW RNA DAMAGE CONTRIBUTES TO GENOMIC INSTABILITY. $850,000 IN NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) R01 FUNDING RECEIVED IN 2025. CHEMOTHERAPY & RNA DAMAGENIMA MOSAMMAPARAST, MD, PHD AND HANI ZAHER, PHD RECEIVED A SIP RDA AWARD IN 2017 FOR THEIR PROJECT, "RNA AS A TARGET OF ALKYLATION CHEMOTHERAPY IN CANCER." THEIR WORK FUNDAMENTALLY CHANGED THE UNDERSTANDING OF HOW CHEMOTHERAPY DAMAGES RNA WITHIN CELLS AND HOW THAT DAMAGE INFLUENCES TUMOR RESPONSE TO TREATMENT. THE FINDINGS HAVE BEEN PUBLISHED IN NUMEROUS HIGH-IMPACT SCIENTIFIC JOURNALS, INCLUDING NATURE AND MOLECULAR CELL, AND CONTINUE TO SHAPE NEW APPROACHES FOR IMPROVING CHEMOTHERAPY EFFECTIVENESS ACROSS MULTIPLE CANCER TYPES. BUILDING ON THESE DISCOVERIES, THE TEAM SECURED ANOTHER MAJOR FEDERAL RESEARCH AWARD TO FURTHER INVESTIGATE THE CONNECTION BETWEEN INNATE IMMUNE SIGNALING AND CANCER THERAPY. $2.5 MILLION IN NATIONAL INSTITUTES OF HEALTH R01 FUNDING WAS RECEIVED IN 2024. BREAST CANCER METASTASISAMIT PATHAK, PHD RECEIVED A SIP RDA AWARD IN 2017 FOR HIS PROJECT, "MEMORY-PLASTICITY CROSSTALK IN CANCER CELLS." HIS RESEARCH EXPLORED WHETHER INVASIVE BREAST CANCER CELLS RETAIN A "MEMORY" OF THE PHYSICAL ENVIRONMENT OF THEIR ORIGINAL TUMOR, A DISCOVERY THAT COULD EXPLAIN HOW METASTATIC TUMORS SPREAD THROUGHOUT THE BODY. THE PROJECT EXPANDED INTO ANIMAL STUDIES AND COMPUTATIONAL MODELING TO IDENTIFY GENE TARGETS CAPABLE OF SLOWING OR PREVENTING METASTASIS. THESE FINDINGS HAVE CONTINUED TO GROW INTO BROADER STUDIES EXAMINING HOW CELLS ADAPT TO CHANGES IN THEIR PHYSICAL ENVIRONMENT AND HOW THOSE CHANGES CONTRIBUTE TO DISEASE. $2.1 MILLION IN NATIONAL INSTITUTES OF HEALTH R35 FUNDING RECEIVED IN 2025. GASTRIC CANCER IMMUNOTHERAPYPATRICIA RIBEIRO PEREIRA, PHD RECEIVED A SIP RDA AWARD IN 2022 FOR HER PROJECT, "THE ROLE OF CAVEOLIN-1 IN GASTRIC CANCER RESPONSE TO IMMUNOTHERAPY." THE PROJECT SOUGHT TO IMPROVE IMMUNOTHERAPY FOR STOMACH CANCER BY USING ADVANCED PET IMAGING TO BETTER UNDERSTAND HOW TUMORS RESPOND TO TREATMENT. DR. PEREIRA'S TEAM DISCOVERED THAT THE PROTEIN CAVEOLIN-1 CAN HIDE TUMOR TARGETS FROM IMMUNOTHERAPIES, LEADING TO THE DEVELOPMENT OF NEW STRATEGIES TO MAKE THESE TREATMENTS MORE EFFECTIVE. THE PROJECT HAS PRODUCED MULTIPLE SCIENTIFIC PUBLICATIONS AND CONTINUES TO ADVANCE RESEARCH INTO IMPROVING IMMUNOTHERAPY FOR BOTH GASTRIC AND BREAST CANCERS. NATIONAL INSTITUTES OF HEALTH/NATIONAL CANCER INSTITUTE R37 MERIT FUNDING RECEIVED IN 2023 TO EXPAND THIS RESEARCH. PROSTATE & PEDIATRIC CANCERHANWEN ZHANG, PHD RECEIVED A SIP RDA AWARD IN 2023 FOR HIS PROJECT, "NEXT GENERATION THERANOSTIC 89ZR/227TH-CONJUGATED PSMA INHIBITOR FOR PRECISION MOLECULAR IMAGING AND RADIOTHERAPY OF METASTATIC PROSTATE CANCER." HIS RESEARCH IS DEVELOPING A NEXT-GENERATION RADIOTRACER CAPABLE OF BOTH DETECTING AND TREATING METASTATIC PROSTATE CANCER WITH GREATER PRECISION. EARLY STUDIES HAVE DEMONSTRATED STRONG RESULTS IN ANIMAL MODELS, PAVING THE WAY FOR FDA APPROVAL AND FUTURE HUMAN CLINICAL TRIALS. THE TECHNOLOGY HAS ALSO SHOWN PROMISE BEYOND PROSTATE CANCER, LEADING TO EXPANSION INTO PEDIATRIC NEUROBLASTOMA RESEARCH. $3 MILLION IN NATIONAL CANCER INSTITUTE R01 FUNDING WAS RECEIVED IN 2024. 6583079 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 44 0 1 12 1 0 0 0 0 0 0 0 0 0 0 0 0 X 30 30 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X X ANGIE PINON 3147871990 9288 DIELMAN INDUSTRIAL DRIVE ST LOUIS MO 63132 DAVID YONCE PRESIDENT 2.00 X X 0 0 0 EMERY SKOLFIELD VICE PRESIDENT 2.00 X X 0 0 0 DAVID MOONS VICE PRESIDENT 2.00 X X 0 0 0 NICK OVERKAMP TREASURER 2.00 X X 0 0 0 RENEE VAN HORN SECRETARY 2.00 X X 0 0 0 BILL TIMMONS IMMEDIATE PAST PRESIDENT 2.00 X X 0 0 0 ED ALIZADEH DIRECTOR (THRU 12/25) 1.00 X 0 0 0 ARGELO ARZANO DIRECTOR 1.00 X 0 0 0 JOE BERGER DIRECTOR 1.00 X 0 0 0 CHRISTIAN BUGYIS DIRECTOR 1.00 X 0 0 0 ASHLEY COX DIRECTOR 1.00 X 0 0 0 TIMOTHY EBERLEIN MD DIRECTOR 1.00 X 0 0 0 RYAN FIELDS MD DIRECTOR (THRU 6/25) 1.00 X 0 0 0 BART FRENCH DIRECTOR 1.00 X 0 0 0 DAIN GIESIE DIRECTOR 1.00 X 0 0 0 JUDY GLIK DIRECTOR 1.00 X 0 0 0 KYLE GRIEGE DIRECTOR 1.00 X 0 0 0 DEBBIE HANKIN DIRECTOR 1.00 X 0 0 0 DENA LADD DIRECTOR 1.00 X 0 0 0 BILL LINDE DIRECTOR 1.00 X 0 0 0 DOUG MANGERS DIRECTOR 1.00 X 0 0 0 MARK MANNING DIRECTOR 1.00 X 0 0 0 JEAN MCDONALD DIRECTOR 1.00 X 0 0 0 MELISSA MERLIN DIRECTOR 1.00 X 0 0 0 RICK MOECKEL DIRECTOR 1.00 X 0 0 0 JAQUI ROGERS DIRECTOR 1.00 X 0 0 0 MICHAEL SCHWARTZ DIRECTOR 1.00 X 0 0 0 SHANE SPEARS DIRECTOR 1.00 X 0 0 0 NICOLE STUBBLEFIELD DIRECTOR 1.00 X 0 0 0 BRAD VERDIGETS DIRECTOR 1.00 X 0 0 0 TED WHEELER DIRECTOR 1.00 X 0 0 0 PETE WYATT DIRECTOR 1.00 X 0 0 0 DAVID DRIER EXECUTIVE DIRECTOR 40.00 X 236766 0 11629 ELEANOR GOEDEKE DIRECTOR OF COMMUNICATIONS & MARKETING 40.00 X 125529 0 19357 ASHLEY SAITTA SENIOR DIRECTOR OF OPERATIONS 40.00 X 145321 0 3112 PAM MANDELKER DIRECTOR OF DEVELOPMENT 32.00 X 147219 0 12471 JULES MCCORMICK DIRECTOR OF EVENTS 40.00 X 105536 0 11213 760371 0 57782 5 0 1 0 BIG SHARK BICYCLE CO 1155 BIG BEND SAINT LOUIS MO 63117 COURSE MANAGEMENT 117507 1 104448 6885644 198093 6990092 RIDER REGISTRATION FEE 900099 318912 318912 318912 109535 109535 9800 104448 104448 -94648 -94648 37400 22399 15001 15001 7338892 333913 0 14887 5042167 5042167 248395 84562 163833 818817 601683 119957 97177 12000 8550 1829 1621 103726 64042 18410 21274 79674 45414 15138 19122 3686 3686 90465 90465 234496 9803 224693 38971 9351 29620 82699 19848 62851 48334 11600 36734 28479 28479 21421 5141 16280 12468 12468 EVENT AND DEVELOPMENT 884645 821223 63422 BAD DEBTS 2500 2500 7752943 6583079 404758 765106 500 193 918229 940100 2034851 1697402 94891 16925 10919 6378 87764 71889 37297 15875 94354 73909 3191041 2750782 112466 112798 94093 67553 206559 180351 X 839748 734980 2144734 1835451 2984482 2570431 3191041 2750782 -414051 0 X 0 1 X 1 0 X 5604297 6030969 6695334 9051296 6990092 34371988 5604297 6030969 6695334 9051296 6990092 34371988 1007226 33364762 20685 40528 96012 109535 266760 34638748 1981266 0.96320 0.96360 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 87764 71889 15875 15875 OPERATING LEASE LIABILITY 67553 67553 X 7723888 258149 126847 384996 7338892 0 7338892 8137939 258149 126847 384996 7752943 0 7752943 PART X, LINE 2: THE ORGANIZATION QUALIFIES AS A NONPROFIT ORGANIZATION AND IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE ORGANIZATION HAS ADDRESSED THE PROVISIONS OF ASC 740, ACCOUNTING FOR INCOME TAXES. IN THAT REGARD, THE ORGANIZATION HAS EVALUATED ITS TAX POSITIONS, EXPIRING STATUTES OF LIMITATIONS, AUDITS, PROPOSED SETTLEMENTS, CHANGES IN TAX LAW, AND NEW AUTHORITATIVE RULINGS AND BELIEVES THAT NO PROVISION FOR INCOME TAXES IS NECESSARY, AT THIS TIME, TO COVER ANY UNCERTAIN TAX POSITIONS. PART XI, LINE 2D - OTHER ADJUSTMENTS: RECLASS OF COST OF GOODS SOLD AGAINST INCOME 22,399. RECLASS OF DIRECT FUNDRAISING EXPENSES AGAINST INCOME 104,448. PART XII, LINE 2D - OTHER ADJUSTMENTS: RECLASS OF COST OF GOODS SOLD AGAINST INCOME 22,399. RECLASS OF DIRECT FUNDRAISING EXPENSES AGAINST INCOME 104,448. TASTE THE CAUSE 114248 104448 9800 104448 114248 104448 9800 104448 104448 -94648 1 SITEMAN KIDS AT STL CHILDREN'S HOSPITAL (STL CHILDREN'S HOSP FOUND) 1001 HIGHLANDS PLAZA DR WEST 160 ST LOUIS MO 631101337 431626863 501(C)(3) 1566667 0 SUPPORT CANCER RESEARCH SITEMAN CANCER CENTER (FOUNDATION FOR BARNES JEWISH HOSP) 1001 HIGHLANDS PLAZA DR WEST 140 ST LOUIS MO 631101337 431648435 501(C)(3) 3475500 0 SUPPORT CANCER RESEARCH 2 0 PART I, LINE 2: PEDAL THE CAUSE (PTC) MAINTAINS RECORDS TO SUBSTANTIATE THE AMOUNT OF ASSISTANCE AWARDED. PTC PROVIDES FUNDING TO SITEMAN CANCER CENTER (THROUGH BARNES JEWISH HOSPITAL FOUNDATION) AND SITEMAN KIDS AT ST. LOUIS CHILDREN'S HOSPITAL (THROUGH THE ST. LOUIS CHILDREN'S HOSPITAL FOUNDATION). BOTH ORGANIZATIONS CONDUCT CANCER RESEARCH AND ARE RECOGNIZED AS TAX-EXEMPT ORGANIZATIONS UNDER INTERNAL REVENUE CODE SECTION 501(C)(3). PTC DOES NOT PRESENTLY FUND CANCER RESEARCH BY OTHER ORGANIZATIONS. X X 0 0 0 0 0 0 0 1 0 DAVID DRIER EXECUTIVE DIRECTOR 191766 0 45000 0 0 0 3000 0 8629 0 248395 0 0 0 PAM MANDELKER DIRECTOR OF DEVELOPMENT 132219 0 15000 0 0 0 0 0 12471 0 159690 0 0 0 PART I, LINE 7 THE BONUS POOL AGGREGATE AMOUNT IS A LINE ITEM IN THE ANNUAL BUDGET, APPROVED BY THE BOARD OF DIRECTORS. ALL EMPLOYEES ARE ELIGIBLE FOR A PORTION OF THE BONUS POOL, BUT NONE ARE GUARANTEED A PAYMENT, NOR IS THE AMOUNT GUARANTEED. BONUS PAYOUT IS AT THE DISCRETION OF THE EXECUTIVE COMMITTEE. THEY DETERMINE IF THE FULL POOL IS TO BE PAID, OR A PORTION THEREOF, BASED ON THE PERFORMANCE OF THE STAFF IN TERMS OF MEETING BUDGETARY EXPECTATIONS. ONCE THE EXECUTIVE COMMITTEE HAS AUTHORIZED THE BONUS AMOUNT TO BE PAID, THE BOARD PRESIDENT, IN CONSULTATION WITH THE EXECUTIVE DIRECTOR, DECIDE ON A PER STAFF PERSON AMOUNT TO BE PAID. THESE AMOUNTS ARE COMMUNICATED AS PART OF THE YEAR-END PERFORMANCE REVIEWS WITH EACH STAFF MEMBER, AND PAID BEFORE THE END OF THE CALENDAR YEAR IN A SPECIAL PAYROLL. X 14 93645 PUBLICLY TRADED EXCHANGE X EVENT MEALS 12 104448 COMPARABLE SALES 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTIONS RATHER THAN THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 4 THE ORGANIZATION AMENDED THEIR BYLAWS DURING THE 2025 TAX YEAR. SIGNIFICANT CHANGES INCLUDE: - THERE IS NO LONGER A MAXIMUM OF 25 BOARD MEMBERS. THE EXACT NUMBER OF DIRECTORS IS TO BE DETERMINED BY RESOLUTION OF THE BOARD FROM TIME TO TIME. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS INITIALLY PREPARED BY THE OUTSIDE ACCOUNTANT. A DRAFT COPY OF THE RETURN IS PROVIDED TO MANAGEMENT FOR REVIEW. CHANGES, IF ANY, ARE DISCUSSED AND A FINAL COPY OF FORM 990 IS PRESENTED TO THE FINANCE COMMITTEE FOR REVIEW. UPON REVIEW BY THE FINANCE COMMITTEE, A COPY OF FORM 990 IS MADE AVAILABLE TO THE BOARD OF DIRECTORS FOR APPROVAL PRIOR TO FILING WITH IRS. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO ALL DIRECTORS AND OFFICERS OF PEDAL THE CAUSE, AND ANY OTHER PERSON WHO IS IN A POSITION TO EXERCISE SUBSTANTIAL INFLUENCE OVER THE DECISIONS AND AFFAIRS OF THE CORPORATION. EACH COVERED PERSON WILL ANNUALLY SIGN A STATEMENT THAT AFFIRMS SUCH PERSON 1) HAS RECEIVED A COPY OF THE POLICY; 2) HAS READ AND UNDERSTANDS THE POLICY; 3) HAS AGREED TO COMPLY WITH THE POLICY; AND 4) UNDERSTANDS THAT THE CORPORATION IS EXEMPT FROM FEDERAL INCOME TAX AND TO MAINTAIN ITS FEDERAL TAX EXEMPTION THE CORPORATION MUST ENGAGE PRIMARILY IN ACTIVITIES THAT ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES. TO ENSURE THAT THE CORPORATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT PURPOSES AND THAT IT DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE ITS STATUS AS AN ORGANIZATION EXEMPT FROM FEDERAL INCOME TAX, THE BOARD WILL CONDUCT PERIODIC REVIEWS. THE PERIODIC REVIEWS WILL, AT A MINIMUM, INCLUDE THE FOLLOWING SUBJECTS: 1) WHETHER THE CORPORATION'S COMPENSATION ARRANGEMENTS ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION, AND ARE THE RESULT OF ARM'S- LENGTH BARGAINING; 2) WHETHER TRANSACTION AND ARRANGEMENTS WITH OTHER ENTITIES AND INDIVIDUALS CONFORM TO THE CORPORATION'S POLICIES, ARE PROPERLY RECORDED, REFLECT REASONABLE PAYMENTS FOR GOODS AND SERVICES, FURTHER THE CORPORATION'S TAX-EXEMPT PURPOSES AND DO NOT RESULT IN PRIVATE INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT, OR IN AN EXCESS BENEFIT TRANSACTION. WHEN CONDUCTING REVIEWS, THE BOARD SHOULD RELY ON APPROPRIATE OUTSIDE EXPERTS (ATTORNEYS, APPRAISERS, OR COMPENSATION OR OTHER CONSULTANTS). FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION OF THE EXECUTIVE DIRECTOR IS APPROVED BY THE EXECUTIVE COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION ADDRESSES REQUESTS TO VIEW GOVERNING DOCUMENTS, THE CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ON A CASE BY CASE BASIS.